Pharmacogenomic heterogeneity of <i>N-acetyltransferase 2</i> : a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review
Further studies exploring the risk of <i>NAT2</i> SNPs in different AT-DILI patients with larger sample sizes and a population-specific approach are required to establish a policy for <i>NAT2</i> genotyping as a pre-emptive biomarker for AT-DILI monitoring for personalized isoniazid therapy in clinics.
Authors
- Kavitha Saravu (ORCID: https://orcid.org/0000-0001-6399-1129)
- Muralidhar Varma (ORCID: https://orcid.org/0000-0002-5546-5353)
- Levin Thomas (ORCID: https://orcid.org/0000-0003-1520-9598)
- Naveen Dutt (ORCID: https://orcid.org/0000-0002-9517-4999)
- Mithu Banerjee (ORCID: https://orcid.org/0000-0002-4107-3076)
- Mahadev Rao (ORCID: https://orcid.org/0000-0003-3322-5399)
- Shrivathsa Kulavalli (ORCID: https://orcid.org/0009-0002-4964-7254)
- S. Chaithra
- Chidananda Sanju SV
- Pankaj Bhardwaj (ORCID: https://orcid.org/0000-0001-9960-3060)
- Y K Batra
- Mitali Mathur
Institutions
- Oklahoma State University (US)
- Manipal Academy of Higher Education (IN)
- International Union Against Tuberculosis and Lung Disease (US)
- All India Institute of Medical Sciences (IN)
- Kasturba Medical College, Manipal (IN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1080/07853890.2025.2478316
- Citations
- 7
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 10.90
Funders
- Indian Council of Medical Research